GW788388

GW788388: sourced facts only. name: "One of the most potent ALK5 inhibitors identified in this chemical series, compound 13d (GW788388)" [1] target: "a potent, selective, and orally active transforming growth factor-beta type I receptor inhibitor" [1] developer: "Department of Medicinal Chemistry and Biology, GlaxoSmithKline, 25-27 Avenue du Québec, 91951 Les Ulis, France." [1] stage: "This compound significantly reduced the expression of collagen IA1 mRNA when administered orally at 10 mg/kg once a day (u.i.d.) in a model of puromycin aminonucleoside-induced renal fibrosis." [1] stage: "One of the most potent ALK5 inhibitors identified in this chemical series, compound 13d (GW788388), reduced the expression of collagen IA1 by 80% at a dose of 1 mg/kg twice a day" [1] modality: "The optimization of a novel phenylpyridine pyrazole series (1a) led to the identification of potent, selective, and orally active ALK5 inhibitors." [1]